• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Carlsmed Inc.

    11/13/25 4:17:58 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care
    Get the next $CARL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Carlsmed, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    14280C105

    (CUSIP Number)


    07/24/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14280C105


    1Names of Reporting Persons

    U.S. Venture Partners XII, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,305,806.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,305,806.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,305,806.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   The reported securities are owned directly by U.S. Venture Partners XII, L.P. ("USVP XII"). Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of each of the USVP XII Funds (as defined below) and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP XII Funds. Dr. Jonathan Root, a member of the Issuer's board of directors, Steven Krausz, Richard Lewis and Dafina Toncheva are the managing members of PMG XII, who may be deemed to share voting and dispositive power over the shares held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 26,592,908 shares of Common Stock outstanding as of November 3, 2025 as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the Commission) on November 6, 2025 ("the Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    14280C105


    1Names of Reporting Persons

    Presidio Management Group XII, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,642,073.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,642,073.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,642,073.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    21.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   Consists of (i) 4,305,806 shares of Common Stock held directly by USVP XII, (ii) 218,524 shares of Common Stock held directly by U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"), and (iii) 1,117,743 shares of Common Stock held directly by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). PMG XII is the general partner of each of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and together with USVP XII and USVP XII-A, USVP SIF, USVP SFI-A, and PMG XII, the "U.S. Venture Partners") is the general partner of USVP SFI and USVP SFI-A. Dr. Jonathan Root, a member of the Issuer's board of directors, Steven Krausz, Richard Lewis and Dafina Toncheva are the managing members of PMG XII, who may be deemed to share voting and dispositive power over the shares held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 26,592,908 shares of Common Stock outstanding as of November 3, 2025 as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    14280C105


    1Names of Reporting Persons

    Casey M Tansey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    200,000.00
    6Shared Voting Power

    5,642,073.00
    7Sole Dispositive Power

    200,000.00
    8Shared Dispositive Power

    5,642,073.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,842,073.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    22.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   Consists of (i) 4,305,806 shares of Common Stock held directly by USVP XII, (ii) 218,524 shares of Common Stock held directly by USVP XII-A, and (iii) 1,117,743 shares of Common Stock held directly by USVP SFI, on its own behalf and as nominee for USVP SFI-A. PMG XII is the general partner of each of USVP XII and USVP XII-A. PMG SFI is the general partner of USVP SFI and USVP SFI-A. Dr. Jonathan Root, a member of the Issuer's board of directors, Steven Krausz, Richard Lewis and Dafina Toncheva are the managing members of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by U.S. Venture Partners. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by U.S. Venture Partners. Each such persons and entities disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The amount beneficially owned by each Reporting Person is determined based on 26,592,908 shares of Common Stock outstanding as of November 3, 2025 as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Carlsmed, Inc.
    (b)Address of issuer's principal executive offices:

    1800 Aston Ave, Suite 100, Carlsbad, CA 92008
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) U.S. Venture Partners XII, L.P., a Delaware limited partnership, (ii) Presidio Management Group XII, L.L.C., a Delaware limited liability company and (iii) Casey M. Tansey, a citizen of the United States (the foregoing entities and individuals are collectively referred to as the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    The principal business office of the Reporting Persons is 1460 El Camino Real, Suite 100, Menlo Park, California 94025.
    (c)Citizenship:

    See Item 2(a)
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    14280C105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    U.S. Venture Partners XII, L.P.
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Authorized Signatory
    Date:11/13/2025
     
    Presidio Management Group XII, L.L.C.
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Authorized Signatory
    Date:11/13/2025
     
    Casey M Tansey
     
    Signature:/s/ Dale Holladay
    Name/Title:Dale Holladay, Attorney-in-Fact
    Date:11/13/2025
    Get the next $CARL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARL

    DatePrice TargetRatingAnalyst
    8/18/2025$19.00Buy
    Goldman
    8/18/2025$18.00Overweight
    Piper Sandler
    8/18/2025$18.00Buy
    Truist
    8/18/2025$21.00Buy
    BTIG Research
    8/18/2025$16.00Buy
    BofA Securities
    More analyst ratings

    $CARL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

    CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET. A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/RczDxtnmshQKpi2ivHQcH3 About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and bey

    4/1/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.  "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o

    2/25/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

    CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healt

    2/23/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President Cordonnier Michael exercised 391,686 shares at a strike of $0.68 and sold $2,629,889 worth of shares (197,855 units at $13.29), increasing direct ownership by 14% to 1,550,477 units (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    3/4/26 4:05:03 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Durall William Scott was granted 44,977 shares (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    1/30/26 5:24:27 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Chief IP Officer Casey Niall was granted 44,977 shares, increasing direct ownership by 5% to 982,562 units (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    1/30/26 5:23:14 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Carlsmed with a new price target

    Goldman initiated coverage of Carlsmed with a rating of Buy and set a new price target of $19.00

    8/18/25 9:56:23 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Carlsmed with a new price target

    Piper Sandler initiated coverage of Carlsmed with a rating of Overweight and set a new price target of $18.00

    8/18/25 9:55:24 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Truist initiated coverage on Carlsmed with a new price target

    Truist initiated coverage of Carlsmed with a rating of Buy and set a new price target of $18.00

    8/18/25 8:55:58 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    SEC Filings

    View All

    SEC Form S-8 filed by Carlsmed Inc.

    S-8 - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:15:33 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Carlsmed Inc.

    10-K - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:09:56 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:05:28 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner B Capital Group Management, L.P. converted options into 6,988,430 shares and bought $19,999,995 worth of shares (1,333,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:51:14 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Director Sidow Kevin was granted 17,333 shares, converted options into 28,900 shares and bought $199,995 worth of shares (13,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:32:18 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Director Mittendorff Robert Ii converted options into 6,988,430 shares and bought $19,999,995 worth of shares (1,333,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:31:12 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Financials

    Live finance-specific insights

    View All

    Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.  "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o

    2/25/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Wednesday, February 25, 2026Time: 1:30 PM Pacific Time Participant Registration: https://register-conf.media-server.com/register/BIb45

    2/11/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance

    Third quarter revenue of $13.1 million, representing 98% growth YoY  Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.  "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and

    11/6/25 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Leadership Updates

    Live Leadership Updates

    View All

    Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

    CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. "We are pleased to welcome Jennifer to the Carlsmed

    9/29/25 9:00:50 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care